Background. Leiomyosarcoma, a mesenchymal malignancy with smooth muscle differentiation, is extremely rare in children. Immunosuppression, due to either antirejection medication in organ transplantation recipients or human immunodeficiency virus infection (HIV), appears to constitute a predispositio
✦ LIBER ✦
Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients
✍ Scribed by Mario Strazzabosco; Barbara Corneo; Rosa Maria Iemmolo; Chiara Menin; Giorgio Gerunda; Laura Bonaldi; Roberto Merenda; Daniele Neri; Alessandro Poletti; Marco Montagna; Annarosa Del Mistro; Alvise Maffei Faccioli; Emma D'Andrea
- Book ID
- 118567679
- Publisher
- Elsevier Science
- Year
- 1997
- Tongue
- English
- Weight
- 834 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Epstein–Barr virus–associated leiomyosar
✍
Charles F. Timmons; D. Brian Dawson; C. Sue Richards; Walter S. Andrews; Julie A
📂
Article
📅
1995
🏛
John Wiley and Sons
🌐
English
⚖ 988 KB
Factors associated with the development
✍
Rafael Mañez; Mary K. Breinig; Peter Linden; Shimon Kusne; Julian Torre-Cisneros
📂
Article
📅
1994
🏛
Springer
🌐
English
⚖ 192 KB
Cellular Immunity to Epstein-Barr Virus
✍
Barbara Savoldo; Cliona M. Rooney; Ruben E. Quiros-Tejeira; Yvette Caldwell; Han
📂
Article
📅
2005
🏛
John Wiley and Sons
🌐
English
⚖ 140 KB
Cellular therapy of Epstein–Barr-virus-a
✍
Helen E. Heslop; Barbara Savoldo; Cliona M. Rooney
📂
Article
📅
2004
🏛
Elsevier Science
🌐
English
⚖ 130 KB
Role of donor versus recipient type Epst
✍
Haque, Tanzina ;Crawford, Dorothy H.
📂
Article
📅
1998
🏛
Springer
🌐
English
⚖ 895 KB
Quantitative Epstein-Barr virus (EBV) se
✍
Erik Verschuuren; Wim van der Bij; Wim de Boer; Wim Timens; Jaap Middeldorp; T.
📂
Article
📅
2002
🏛
John Wiley and Sons
🌐
English
⚖ 145 KB
👁 1 views
## Abstract The Epstein‐Barr virus (EBV)‐specific antibody response was studied in lung transplant patients to assess their value in the diagnosis and prognosis of post‐transplant lymphoproliferative disease. Recently developed synthetic peptides representing Epstein‐Barr nuclear antigen‐1 (EBNA‐1)